Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Companion Diagnostics

Robert Wassman's Biography

Robert Wassman, Chief Medical Officer, Rosetta Genomics

E. Robert Wassman, M.D. is Chief Medical Officer of Rosetta Genomics a pioneer in the discovery of microRNAs and their development into clinical diagnostic tools. Dr. Wassman joined Rosetta with more than 30 years of experience in genetics-based diagnostics. Prior to joining Rosetta, he served in various positions focused on the advancing the translation and delivery of cutting-edge diagnostic technology into clinical service, including Chief Medical and Chief Genomics Officer at Generation Health; SVP/CMO of Helicos BioSciences; Co-Founder and CMO of Good Start Genetics, and President/CMO of Celula, Inc. Prior to leading these start-up ventures, he was the Senior Medical Officer of Genzyme Genetics after helping lead Alfigen/The Genetics Institute for many years. In addition he has served as a consultant to numerous companies introducing other key innovations to the market.
Dr. Wassman received his B.S. from Yale University, and his M.D. from Albany Medical College. He took post-graduate training in Pediatrics and Medical Genetics at NY Hospital-Cornell University Medical Center and UCLA respectively, and is Board certified in these disciplines.

Robert Wassman Image

MicroRNAs as Potential Companion Diagnostics

Tuesday, 28 October 2014 at 08:30

Add to Calendar ▼2014-10-28 08:30:002014-10-28 09:30:00Europe/LondonMicroRNAs as Potential Companion

MicroRNAs represent a novel class of biomarkers that are “Master” regulators of post-transcriptional gene expression. They have already been demonstrated to have clinical utility in oncology diagnostics. Beyond oncology, microRNAs have been demonstrated to play a role in numerous other disease processes and the development of specific assays in other clinical areas is imminent. Their unique biological properties make them stable, specific, and robust for clinical diagnostic purposes and amenable to measurement on multiple platforms. Evidence for their utility in prediction of response to therapy suggest the potential for their evolution into Companion Diagnostics in the near future.

Add to Calendar ▼2014-10-27 00:00:002014-10-28 00:00:00Europe/LondonCompanion